Pharmacological profile of PMS777, a new AChE inhibitor with PAF antagonistic activity
Open Access
- 23 January 2006
- journal article
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 10 (01) , 21-29
Abstract
The key pathophysiological mechanisms in Alzheimer's disease involve the selective loss of cholinergic neurons and pro-inflammatory mediator-relatedKeywords
This publication has 30 references indexed in Scilit:
- Structure−Activity Relationships in Platelet-Activating Factor. 12. Synthesis and Biological Evaluation of Platelet-Activating Factor Antagonists with Anti-HIV-1 ActivityJournal of Medicinal Chemistry, 2004
- Ginkgo biloba Extract EGb 761® in Dementia: Intent-to-treat Analyses of a 24-week, Multi-center, Double-blind, Placebo-controlled, Randomized TrialPharmacopsychiatry, 2003
- Does aspirin protect against Alzheimer's dementia? A study in a Swedish population-based sample aged ?80 yearsEuropean Journal of Clinical Pharmacology, 2003
- Prostaglandins and other lipid mediators in Alzheimer’s diseaseProstaglandins & Other Lipid Mediators, 2002
- Reduction in glial immunity and neuropathology by a PAF antagonist and an MMP and TNFα inhibitor in SCID mice with HIV-1 encephalitisJournal of Neuroimmunology, 2001
- Interaction between neurone and microglia mediated by platelet‐activating factorGenes to Cells, 2000
- Chapter 20 The neuromessenger platelet-activating factor in plasticity and neurodegeneration1998
- Binding of platelet-activating factor to platelets of Alzheimer's disease and multiinfarct Dementia patientsNeurobiology of Aging, 1996
- Platelet-activating factor in the modulation of excitatory amino acid neurotransmitter release and of gene expressionJournal of Lipid Mediators and Cell Signalling, 1996
- Platelet-activating factor (PAF) receptor in rat brain: PAF mobilizes intracellular Ca2+ in hippocampal neuronsNeuron, 1992